Indumathy Varadarajan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Indumathy Varadarajan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ajeetha Ramachandran
Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts
18 shared publications - Amitkumar Mehta
Medicine, University of Alabama at Birmingham, Birmingham, Alabama
18 shared publications - Andrew Krueger
Takeda (United States) 8
18 shared publications - Bradley Hupf
Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts
18 shared publications - Girish Bende
Takeda Development Center Americas, Inc. (TDCA) 10 Cambridge, Massachusetts
18 shared publications - Jennifer N. Saultz
Division of Hematology/Oncology Oregon Health and Science University Portland Oregon USA
18 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S4 shows Interleukin-15, Interleukin-6, Interferon gamma, tumor necrosis factor, granulocyte macrophage colony stimulating factor, interleukin- 8, interleukin-10, interleukin-12 profiles following TAK-007 administration.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S4 shows Interleukin-15, Interleukin-6, Interferon gamma, tumor necrosis factor, granulocyte macrophage colony stimulating factor, interleukin- 8, interleukin-10, interleukin-12 profiles following TAK-007 administration.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S5 shows differential gene expression in Day 0 samples that did versus did not elicit a clinical response, based on pseudobulk analysis.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S5 shows differential gene expression in Day 0 samples that did versus did not elicit a clinical response, based on pseudobulk analysis.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Efficacy analysis conducted in 800M escalation and expansion cohorts. A, Clinical responses at 1 month. B, Kaplan–Meier plot of PFS in 800M dose escalation and expansion cohorts. C, Kaplan–Meier plot of OS in 800M dose escalation and expansion cohorts. D, DOR in 800M dose escalation and expansion cohorts. E, Clinical response across varying target antigen levels measured by immunohistochemistry on tumor biopsies. F, Mean VAF % over time. Each line represents an individual patient. *ORR is defined as the incidence of CR and PR. †Includes patients who had a response at month 1. ‡One patient had a longitudinal sample with a ctDNA result at month 2, plotted here along with the data points labeled as month 3. PD, progressive disease.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Efficacy analysis conducted in 800M escalation and expansion cohorts. A, Clinical responses at 1 month. B, Kaplan–Meier plot of PFS in 800M dose escalation and expansion cohorts. C, Kaplan–Meier plot of OS in 800M dose escalation and expansion cohorts. D, DOR in 800M dose escalation and expansion cohorts. E, Clinical response across varying target antigen levels measured by immunohistochemistry on tumor biopsies. F, Mean VAF % over time. Each line represents an individual patient. *ORR is defined as the incidence of CR and PR. †Includes patients who had a response at month 1. ‡One patient had a longitudinal sample with a ctDNA result at month 2, plotted here along with the data points labeled as month 3. PD, progressive disease.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
TEAEs reported by ≥15% of patients and all corresponding grade ≥3 TEAEs in the safety populationa.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
TEAEs reported by ≥15% of patients and all corresponding grade ≥3 TEAEs in the safety populationa.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Cellular kinetics conducted in the pharmacodynamic set. A, CK profile [mean ± standard error (SE)] in patients receiving TAK-007 (800M). B, Logistic regression of the probability of complete response. The blue line indicates the predicted response (P value using the Wald test: 0.45), whereas the light blue ribbon indicates the 95% CI of the predicted response. Individual Cmax values are shown as colored circles. The minimum exposure thresholds were defined as peak levels (Cmax) of ≥1,000 copies/μg after infusion, with persistence as quantifiable levels for a minimum of 14 days. The desirable exposures associated with meaningful efficacy threshold were defined as peak levels (Cmax) of ≥10,000 copies/μg and persistence for at least 30 days. PD, progressive disease; SD, stable disease.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Cellular kinetics conducted in the pharmacodynamic set. A, CK profile [mean ± standard error (SE)] in patients receiving TAK-007 (800M). B, Logistic regression of the probability of complete response. The blue line indicates the predicted response (P value using the Wald test: 0.45), whereas the light blue ribbon indicates the 95% CI of the predicted response. Individual Cmax values are shown as colored circles. The minimum exposure thresholds were defined as peak levels (Cmax) of ≥1,000 copies/μg after infusion, with persistence as quantifiable levels for a minimum of 14 days. The desirable exposures associated with meaningful efficacy threshold were defined as peak levels (Cmax) of ≥10,000 copies/μg and persistence for at least 30 days. PD, progressive disease; SD, stable disease.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
TEAEs of clinical interest related to TAK-007 in the safety populationa.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
TEAEs of clinical interest related to TAK-007 in the safety populationa.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S1 shows the metabolic tumor volume analysis conducted in all patients who received 800M TAK-007, patients with LBCL who received TAK-007 800M, and in patients iNHL who received TAK-007 800M
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Figure S1 shows the metabolic tumor volume analysis conducted in all patients who received 800M TAK-007, patients with LBCL who received TAK-007 800M, and in patients iNHL who received TAK-007 800M
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Baseline patient demographics and disease characteristics in the modified ITT population.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Baseline patient demographics and disease characteristics in the modified ITT population.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
In relapsed/refractory (r/r) large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR) natural killer (NK) cell therapies offer potential advantages over CAR T-cell therapies, including off-the-shelf availability and scalable manufacturing. We performed a phase II study of single-dose TAK-007, a cryopreserved, cord blood-derived, off-the-shelf CD19 CAR NK-cell therapy, in 26 heavily pretreated patients with r/r B-cell non–Hodgkin lymphoma (NHL). Adverse events were manageable, with limited grade 1 to 2 cytokine release syndrome (11.5%). The overall response rate with TAK-007 800 × 106 CD19 CAR+ viable NK cells (n = 14) was 60.9% [95% confidence interval (CI), 38.5–80.3]. The median progression-free survival was 2 months (95% CI, 0.99–3.58) in LBCL (n = 10) and 5.6 months (95% CI, 1.05–8.57) in indolent NHL (n = 7) expansion cohorts. Deep molecular responses, including circulating tumor DNA–negative responses, were achieved. Not all TAK-007 products elicited clinical responses; single-cell RNA sequencing showed NK proliferating and NK-CD56dim cell enrichment in TAK-007 products eliciting/not eliciting responses, respectively, which could inform product selection. Significance:Patients with r/r B-NHL treated with one dose of cryopreserved 800× 106 TAK-007 (CD19 CAR NK cells) had an overall response rate of 60.9%. The safety profile was favorable. Deep molecular responses were achieved; cell subsets that could improve outcomes and inform future product selection were identified.See related commentary by Duléry et al., p. 856
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
In relapsed/refractory (r/r) large B-cell lymphoma (LBCL), chimeric antigen receptor (CAR) natural killer (NK) cell therapies offer potential advantages over CAR T-cell therapies, including off-the-shelf availability and scalable manufacturing. We performed a phase II study of single-dose TAK-007, a cryopreserved, cord blood-derived, off-the-shelf CD19 CAR NK-cell therapy, in 26 heavily pretreated patients with r/r B-cell non–Hodgkin lymphoma (NHL). Adverse events were manageable, with limited grade 1 to 2 cytokine release syndrome (11.5%). The overall response rate with TAK-007 800 × 106 CD19 CAR+ viable NK cells (n = 14) was 60.9% [95% confidence interval (CI), 38.5–80.3]. The median progression-free survival was 2 months (95% CI, 0.99–3.58) in LBCL (n = 10) and 5.6 months (95% CI, 1.05–8.57) in indolent NHL (n = 7) expansion cohorts. Deep molecular responses, including circulating tumor DNA–negative responses, were achieved. Not all TAK-007 products elicited clinical responses; single-cell RNA sequencing showed NK proliferating and NK-CD56dim cell enrichment in TAK-007 products eliciting/not eliciting responses, respectively, which could inform product selection. Significance:Patients with r/r B-NHL treated with one dose of cryopreserved 800× 106 TAK-007 (CD19 CAR NK cells) had an overall response rate of 60.9%. The safety profile was favorable. Deep molecular responses were achieved; cell subsets that could improve outcomes and inform future product selection were identified.See related commentary by Duléry et al., p. 856
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Table 1 shows the representativeness of study patients.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Phase II, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non–Hodgkin Lymphoma
Supplementary Table 1 shows the representativeness of study patients.